Article ISI
ANNALS OF ONCOLOGY  (2022)

Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: Additional response outcomes from RELATIVITY-047

Hodi, F. S.; Tawbi, H. A.; Lipson, E. J.; Schadendorf, D.; Ascierto, P. A.; Matamala, L. A.; Salman, P.; Gutierrez, E. C.; Rutkowski, P.; Gogas, H. J.; Lao, C. D.; Menezes, J.; Dalle, S.; Arance Fernandez, A. M.; Grob, J. J.; et. al.